# Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD

> **NCT02680756** · PHASE3 · COMPLETED · sponsor: **Shield Therapeutics** · enrollment: 250 (actual)

## Conditions studied

- Anemia, Iron-Deficiency
- Inflammatory Bowel Disease
- Crohn's Disease

## Interventions

- **DRUG:** Ferric Maltol
- **DRUG:** Ferric Carboxy Maltose

## Key facts

- **NCT ID:** NCT02680756
- **Lead sponsor:** Shield Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2018-10
- **Final completion:** 2019-01
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2020-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02680756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02680756, "Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02680756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*